Dynamic changes and multiplication rate of white blood cell count may direct the timing of cytoreduction chemotherapy during induction treatment in newly diagnosed acute promyelocytic leukemia with low-intermediate risk.

APL WBC cytoreduction chemotherapy induction treatment initiation time low-intermediate risk multiplication rate

Journal

Molecular and clinical oncology
ISSN: 2049-9450
Titre abrégé: Mol Clin Oncol
Pays: England
ID NLM: 101613422

Informations de publication

Date de publication:
Jun 2021
Historique:
received: 20 12 2020
accepted: 12 03 2021
entrez: 27 4 2021
pubmed: 28 4 2021
medline: 28 4 2021
Statut: ppublish

Résumé

In order to explore the optimal timing for initiating cytoreduction chemotherapy following all-trans retinoic acid plus arsenic trioxide administration, 58 newly diagnosed patients with acute promyelocytic leukemia (APL) with low-intermediate mortality risk were retrospectively analyzed. During induction treatment, white blood cell (WBC) count >4x10

Identifiants

pubmed: 33903818
doi: 10.3892/mco.2021.2274
pii: MCO-0-0-02274
pmc: PMC8060852
doi:

Types de publication

Journal Article

Langues

eng

Pagination

112

Informations de copyright

Copyright: © Wen et al.

Déclaration de conflit d'intérêts

The authors declare that they have no competing interests.

Références

Blood. 1999 Nov 1;94(9):3015-21
pubmed: 10556184
Am J Clin Oncol. 1982 Dec;5(6):649-55
pubmed: 7165009
Blood. 1993 Dec 1;82(11):3241-9
pubmed: 8241496
Blood. 1997 Aug 1;90(3):1014-21
pubmed: 9242531
Ann Intern Med. 1992 Aug 15;117(4):292-6
pubmed: 1637024
Blood. 2000 Aug 15;96(4):1247-53
pubmed: 10942364
Blood. 2010 Jun 24;115(25):5137-46
pubmed: 20393132
J Natl Compr Canc Netw. 2017 Jul;15(7):926-957
pubmed: 28687581
Biomed Rep. 2018 Sep;9(3):227-232
pubmed: 30271598
N Engl J Med. 2013 Jul 11;369(2):111-21
pubmed: 23841729
Blood. 2019 Apr 11;133(15):1630-1643
pubmed: 30803991
J Clin Oncol. 2003 Dec 15;21(24):4642-9
pubmed: 14673054
Trials. 2018 Sep 5;19(1):476
pubmed: 30185214

Auteurs

Jingjing Wen (J)

Department of Hematology, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, Sichuan 621000, P.R. China.

Fang Xu (F)

Department of Hematology, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, Sichuan 621000, P.R. China.

Qiaolin Zhou (Q)

Department of Hematology, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, Sichuan 621000, P.R. China.

Hong Hu (H)

Department of Hematology, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, Sichuan 621000, P.R. China.

Yiping Liu (Y)

Department of Hematology, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, Sichuan 621000, P.R. China.

Jing Su (J)

Department of Hematology, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, Sichuan 621000, P.R. China.

Ya Zhang (Y)

Department of Hematology, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, Sichuan 621000, P.R. China.

Wen Qu (W)

Department of Hematology, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, Sichuan 621000, P.R. China.

Lin Shi (L)

Department of Hematology, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, Sichuan 621000, P.R. China.

Classifications MeSH